Journals / Medicine Science / 2022 / Cilt: 11 - Sayı: 2

Engineering, production, and immunogenicity studies of a truncated form of rabies virus glycoprotein produced in Nicotiana benthamiana plant

Pages
478–483
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Plant-produced G-protein could be a cost-effective, safe and highly immunogenic rabies vaccine candidate.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Rabies is a viral disease caused by the rabies virus (Lyssavirus) that affects the central nervous system, ultimately leading to death and brain disease.
📊
Key Findings & Data:Rabies is 100% fatal if untreated and ultimately causing more than 70,000 deaths annually worldwide, especially among children in developing countries.
💡
Conclusion & Impact:Plant-produced G-protein could be a cost-effective, safe and highly immunogenic rabies vaccine candidate.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Rabies is a viral disease caused by the rabies virus (Lyssavirus) that affects the central nervous system, ultimately leading to death and brain disease. Rabies usually transmitted through a bite among domestic dogs and wild carnivorous animals. The rabies virus (RABV) infects the central nervous system causing disease in the brain and death. Rabies is 100% fatal if untreated and ultimately causing more than 70,000 deaths annually worldwide, especially among children in developing countries. Rabies can be prevented by vaccination and can be cured immediately after infection. Although several human and animal vaccines against rabies are available, they are expensive, have relatively low immunogenicity and also difficult to produce. Therefore, less expensive, more immunogenic and safe rabies vaccines that can be produced in the large quantities are urgently needed. The transient plant expression system has become a more attractive and promising platform for the expression of a wide range of recombinant proteins such as vaccines, antibodies, therapeutic proteins, including mammalian complex proteins. In this study, we engineered and produced a truncated form of glycoprotein (G protein) of rabies virus in Nicotiana benthamiana (N. benthamiana) plant for the first time, using transient expression system. Plant produced RG2 protein was purified through Ni-NTA column chromatography. The purification yield of RG2 protein was ~32 mg/ kg plant leaf. The results of immunogenicity studies showed that the plant produced G-protein elicited significantly high antibody titers in mice. Plant-produced G-protein could be a cost-effective, safe and highly immunogenic rabies vaccine candidate.

🔖

Cite This Article

MAMEDOV, T., MAMMADOVA, G., MUTLU, N., GUN, N., GÜRBÜZASLAN, İ., YÜKSEL, D., HASANOVA, G. (2022). Engineering, production, and immunogenicity studies of a truncated form of rabies virus glycoprotein produced in Nicotiana benthamiana plant. Medicine Science, Cilt: 11 - Sayı: 2, 478–483. https://ajindex.com/articles/579600

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Dietzschold B, Schnell M, Koprowski H. Pathogenesis of rabies. Curr Top Microbiol Immunol. 2005;292:45-56
  2. Knobel DL, Cleaveland S, Coleman PG, et al. Re-evaluating the burden of rabies in Africa and Asia. Bull World Health Organ. 2005;83:360-8
  3. Dhingra V, Li X, Liu Y, Fu ZF. Proteomic profiling reveals that rabies virus infection results in differential expression of host proteins involved in ion homeostasis and synaptic physiology in the central nervous system. J Neurovirol. 2007;13:107-17
  4. Gillet JP, Derer P, Tsiang H. Axonal transport of rabies virus in the central nervous system of the rat. J Neuropathol Exp Neurol. 1986;45:619-34
  5. Davis BM, Rall GF, Schnell MJ. Everything You Always Wanted to Know About Rabies Virus (But Were Afraid to Ask). Annu Rev Virol. 2015;2:451-71
  6. Fletcher MA, Hessel L, Plotkin SA. Human diploid cell strains (HDCS) viral vaccines. Developments in Biological Standardization. 1998;93:97-107
  7. Dhankhar P, Vaidya SA, Fishbien DB, Meltzer MI. Cost effectiveness of rabies post exposure prophylaxis in the United States. Vaccine. 2008;26: 4251–5
  8. Freuling C, Selhorst T, Batza HJ, Muller T. The financial challenge of keeping a large region rabies-free– the EU example. Dev Biol. 2008;131:273–282
  9. Schnell MJ, McGettigan JP, Wirblich C, Papaneri A. The cell biology of rabies virus: using stealth to reach the brain. Nat Rev Microbiol. 2010;8:51-61
  10. Foley HD, McGettigan JP, Siler CA, Dietzschold B, Schnell MJ. A recombinant rabies virus expressing vesicular stomatitis virus glycoprotein fails to protect against rabies virus infection. Proc Natl Acad Sci USA. 2000;97:14680-5
  11. Macfarlan RI, Dietzschold B, Koprowski H. Stimulation of cytotoxic T-lymphocyte responses by rabies virus glycoprotein and identification of an immunodominant domain. Mol Immunol. 1986;23:733-41
  12. Gaudin Y, Ruigrok RW, Tuffereau C, Knossow M, Flamand A. Rabies virus glycoprotein is a trimer. Virology. 1992; 187:627–32
  13. Prehaud C, Takehara K, Flamand A, Bishop DH. Immunogenic and protective properties of rabies virus glycoprotein expressed by baculovirus vectors. Virology. 1989;173:390-9
  14. Ashraf S, Singh PK, Yadav DK, et al. High level expression of surface glycoprotein of rabies virus in tobacco leaves and its immunoprotective activity in mice. J Biotechnol. 2005;119:1-14
  15. Yokomizo AY, Jorge SA, Astray RM, et al. Rabies virus glycoprotein expression in Drosophila S2 cells. I. Functional recombinant protein in stable co-